- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05675943
Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in Patients With Hematological Disorders Who Are Persistently Positive for COVID-19
April 13, 2023 updated by: Beijing Boren Hospital
A Multicenter, Randomized, Single-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in the Treatment of Patients With Hematological Disorders Who Are Persistently Positive for the Covid-19
This study is a multicenter, randomized, single-blind, placebo-controlled clinical trial to evaluate the effectiveness and safety of Anti-COVID-19 Antibody SA55 for Injection in patients with hematological malignancies.
This study consists of two stages.
In the first stage, 8 subjects aged 18-75 were recruited for safety assessment, including the monitoring of clinical test indicators and adverse events.
After confirming the preliminary safety results of the first stage, we plan to recruit 160 COVID-19 patients with hematologic disorders aged 1-75 years old and randomly divided into the SA55 group and the placebo group with a ratio of 3:1.
Basic information and laboratory tests will be collected during the whole study, and the occurrence of adverse events and SAEs of all subjects were collected.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
160
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100070
- Recruiting
- Beijing Boren Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 75 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Subjects in this study must meet all of the following criteria:
- Male or female patients with hematological malignancies who are in stable condition or with bone marrow failure disorders and aged from 1 to 75 years old on the day of enrollment;
- On the day of enrollment, the subject was judged to be positive for Covid-19 nucleic acid/antigen for more than 10 days without turning negative or had turned negative but recovered positive again after 10 days;
- On the day of enrollment, patients who have received CAR T-cell therapy, corticosteroids for a long time or other immuno-suppressive drugs, with the proportion of peripheral blood B cells is less than 2%;
- Subjects (men and women with childbearing potential) and their sexual partners voluntarily take effective contraceptive measures from 4 weeks before screening to 3 months after the last dose of the test drug, and have no plan to donate sperm or eggs;
- Subjects voluntarily participate in the trial and sign the informed consent form before the study begins.
Exclusion Criteria:
Those who meet any of the following conditions will be excluded:
- Those who are known to be allergic to the test drug and any component in the preparation, or other similar drugs;
- Complications requiring surgery within 7 days, or complication considered life-threatening within 28 days;
- Received treatment with SARS-CoV-2 neutralizing antibody drugs before screening;
- Convalescent plasma from recovered patients before screening;
- Patients who took anti-SARS-CoV-2 drugs within 48 hours before enrollment, including but not limited to Paxlovid (Nirmatrelvir/Ritonavir), Azvudine, Molnupiravir, etc.
- On the day of enrollment, meet the diagnostic criteria for severe/critical new coronavirus pneumonia;
- Suspected to have been combined with active bacteria, fungi, viruses or other infections other than the new coronavirus;
- Those who plan to become pregnant, are pregnant, or are breastfeeding;
- Participated in clinical trials of SARS-CoV-2 neutralizing antibody drugs within 180 days before screening or participated in clinical trials of other drugs or medical devices within 4 weeks before screening;
- Suffering from severe neurological diseases (epilepsy, convulsions or convulsions) or mental illness, with a family history of mental illness;
- Suffering from other serious diseases that are not controlled, such as severe cardiovascular and cerebrovascular diseases, liver and kidney diseases, endocrine system diseases; or other diseases that the researchers judge are not suitable for participating in the study (such as currently uncontrolled autoimmune diseases, etc. );
- Other conditions that the researcher believes are not suitable for participating in this study due to various reasons.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anti-COVID-19 Antibody SA55 for Injection
|
After the subjects are successfully screened, according to the group they belong to, they will be given the corresponding drug by intramuscular injection once (the dose of SA55 injection for subjects 40kg and above in the test group is 600mg (4ml), and the dose of SA55 injection for subjects in the test group below 40kg is 300mg (2ml), the subjects in the placebo group who are 40kg and above are injected with 4ml of placebo, and those in the test group under 40kg are injected with 2ml of placebo.The injection is allowed in both deltoid muscle of the upper arm or the buttocks muscle.
|
Placebo Comparator: Placebo
Anti-COVID-19 Antibody SA55 for Injection administered intramuscular
|
After the subjects are successfully screened, according to the group they belong to, they will be given the corresponding drug by intramuscular injection once (the dose of SA55 injection for subjects 40kg and above in the test group is 600mg (4ml), and the dose of SA55 injection for subjects in the test group below 40kg is 300mg (2ml), the subjects in the placebo group who are 40kg and above are injected with 4ml of placebo, and those in the test group under 40kg are injected with 2ml of placebo.The injection is allowed in both deltoid muscle of the upper arm or the buttocks muscle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time when the subject has nucleic acid and the antigen test continues to turn negative
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of Subjects Progressing to Severe/Critical
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
Proportion of subjects who died from any cause
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
Proportion of subjects admitted to ICU
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
Number of days a case was admitted to the ICU
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
Proportion of subjects with severe/critical illness or all-cause death related to COVID-19
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
The incidence of AEs
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
The incidence of SAEs
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
Time of subject's shock correction
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
Proportion of subjects requiring oxygen therapy
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
Proportion of subjects requiring non-invasive ventilation
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
Proportion of subjects requiring mechanical ventilation
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
Days of subject's hospitalization from dosing
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
Change of CT value
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
Proportion of patients with negative persistent nucleic acid test(NAT)(key secondary endpoint)
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 9, 2023
Primary Completion (Anticipated)
January 31, 2024
Study Completion (Anticipated)
May 31, 2024
Study Registration Dates
First Submitted
January 6, 2023
First Submitted That Met QC Criteria
January 6, 2023
First Posted (Actual)
January 9, 2023
Study Record Updates
Last Update Posted (Actual)
April 18, 2023
Last Update Submitted That Met QC Criteria
April 13, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Disease
- Hematologic Diseases
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies
Other Study ID Numbers
- PRO-SA55-0004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
Clinical Trials on Anti-COVID-19 Antibody SA55 for Injection
-
Sinovac Life Sciences Co., Ltd.Recruiting
-
Universitas Sebelas MaretCompleted
-
Dermama Bioteknologi LaboratoriumKementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, IndonesiaRecruitingSARS-CoV2 InfectionIndonesia
-
Methodist Health SystemRecruiting
-
Jens D Lundgren, MDMinistry of the Interior and Health, DenmarkCompletedSARS-CoV InfectionDenmark
-
Kanuni Sultan Suleyman Training and Research HospitalCompletedCovid-19 | Risk Factor, MortalityTurkey
-
Assiut UniversityCompletedCOVID-19 | Cataract SurgeryEgypt
-
Scripps Translational Science InstituteCue HealthRecruitingImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised IndividualsHIV Infections | Lymphoma | Leukemia | Cancer | Multiple Myeloma | Immunosuppression | Immunodeficiency | Transplant | Graft Versus Host Disease | Age-Related ImmunodeficiencyUnited States
-
Cairo UniversityCompleted
-
Hôpital Européen MarseilleUnknownCovid19 | Virus-HIVFrance